# Phase 3 Liver Cirrhosis trials recruiting: 22 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 22 trials in phase 3 for Liver Cirrhosis that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Liver Cirrhosis trials: 22 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/liver-cirrhosis

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 22
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 22 newest of 22, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 6, 2026 | NCT07860710 | J-LINX: Japan LINerixibat eXtension Study | GlaxoSmithKline | Phase 3 | Not yet recruiting | Pruritus | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07860710) |
| October 2, 2026 | NCT07854782 | Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Regeneron Pharmaceuticals | Phase 3 | Recruiting | Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07854782) |
| July 24, 2026 | NCT07726693 | Apixaban to Prevent Decompensation of Early Liver Cirrhosis Trial | University College, London | Phase 3 | Not yet recruiting | Liver Cirrhosis | 1,142 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07726693) |
| April 14, 2026 | NCT07529262 | Can Aspirin Reduce the Risk of HCC in Cirrhosis: The AspiRe HCC Trial | Curtin University | Phase 3 | Not yet recruiting | Liver Cirrhosis | 890 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07529262) |
| February 20, 2026 | NCT07424677 | Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy | Zydus Therapeutics Inc. | Phase 3 | Recruiting | Primary Biliary Cholangitis | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07424677) |
| February 17, 2026 | NCT07412236 | A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic... | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Recruiting | Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B | 1,208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07412236) |
| December 22, 2025 | NCT07296458 | FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy | Xijing Hospital of Digestive Diseases | Phase 3 | Recruiting | Primary Biliary Cholangitis (PBC) | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296458) |
| December 15, 2025 | NCT07282353 | A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA | Cascade Pharmaceuticals, Inc | Phase 3 | Recruiting | Primary Biliary Cholangitis | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282353) |
| October 14, 2025 | NCT07216235 | Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on... | Zydus Therapeutics Inc. | Phase 3 | Recruiting | Primary Biliary Cholangitis | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07216235) |
| February 7, 2025 | NCT06814626 | Role of Nutritional Intervention for the Treatment of Sarcopenia in Cirrhotic Patients With Refractory Ascites Candidate to Transjugular... | The Mediterranean Institute for Transplantation and Advanced Specialized Therapies | Phase 3 | Recruiting | Liver Cirrhosis, Refractory Ascites in Patients With Cirrhosis, Sarcopenia in Liver Cirrhosis | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06814626) |
| January 1, 2025 | NCT06755541 | Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study | Xijing Hospital of Digestive Diseases | Phase 3 | Recruiting | Primary Biliary Cholangitis (PBC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755541) |
| January 1, 2025 | NCT06755151 | Fenofibrate in Primary Biliary Cholangitis: a Real World Study | Xijing Hospital of Digestive Diseases | Phase 3 | Recruiting | Primary Biliary Cholangitis (PBC) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06755151) |
| October 9, 2024 | NCT06632444 | LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver... | Boehringer Ingelheim | Phase 3 | Recruiting | Metabolic Dysfunction Associated Steatohepatitis (MASH), Liver Fibrosis | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06632444) |
| June 14, 2024 | NCT06461208 | A PROspective Faecal MIcrobiota tranSplantation Trial to Improve outcomEs in Patients With Cirrhosis | King's College London | Phase 3 | Recruiting | Liver Cirrhosis | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06461208) |
| September 25, 2023 | NCT06051617 | Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Gilead Sciences | Phase 3 | Recruiting | Primary Biliary Cholangitis | 402 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06051617) |
| August 30, 2023 | NCT06016842 | A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Ipsen | Phase 3 | Recruiting | Primary Biliary Cholangitis (PBC) | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06016842) |
| June 15, 2023 | NCT05905172 | Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis | Beijing Continent Pharmaceutical Co, Ltd. | Phase 3 | Recruiting | Liver Fibrosis | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05905172) |
| March 2, 2023 | NCT05751967 | Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis | Xijing Hospital of Digestive Diseases | Phase 3 | Recruiting | Primary Biliary Cholangitis | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05751967) |
| December 30, 2020 | NCT04689152 | Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis | Pharmicell Co., Ltd. | Phase 3 | Recruiting | Alcoholic Cirrhosis | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04689152) |
| December 10, 2018 | NCT03770936 | Effect of Some Drugs on Liver Fibrosis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Liver Fibroses | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03770936) |
| July 6, 2016 | NCT02823366 | Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | Phase 3 | Recruiting | Primary Biliary Cirrhosis | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02823366) |
| April 22, 2015 | NCT02423395 | Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis | Sponsor not shown (see the record) | Phase 3 | Recruiting | Liver Cirrhosis, Muscle Cramps | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02423395) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Xijing Hospital of Digestive Diseases | 5 |
| Zydus Therapeutics Inc. | 2 |
| [Beijing Continent Pharmaceutical Co, Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-continent-pharmaceutical-co-ltd) | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| Pharmicell Co., Ltd. | 1 |
| [Ipsen](https://specstream.ai/data/clinical-trials/company/ipsen) | 1 |
| The Mediterranean Institute for Transplantation and Advanced Specialized Therapies | 1 |
| King's College London | 1 |
| University College, London | 1 |
| Curtin University | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Cascade Pharmaceuticals, Inc | 1 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 10 |
| United States | 6 |
| Italy | 4 |
| South Korea | 4 |
| Argentina | 3 |
| Australia | 3 |
| Belgium | 3 |
| Canada | 3 |
| Chile | 3 |
| Czechia | 3 |
| France | 3 |
| Hungary | 3 |
| Mexico | 3 |
| Poland | 3 |
| Romania | 3 |
| Spain | 3 |
| Switzerland | 3 |
| United Kingdom | 3 |
| Austria | 2 |
| Brazil | 2 |
| Bulgaria | 2 |
| Germany | 2 |
| Hong Kong | 2 |
| Malaysia | 2 |
| New Zealand | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Trailer rental companies in the United States](https://specstream.ai/data/businesses/trailer-rental-companies/united-states)
- [Cleaning products suppliers in the United States](https://specstream.ai/data/businesses/cleaning-products-suppliers/united-states)
- [Internal medicine practices in the United States](https://specstream.ai/data/businesses/internal-medicine-practices/united-states)
- [Sand and gravel suppliers in the United States](https://specstream.ai/data/businesses/sand-and-gravel-suppliers/united-states)
- [B2B transportation and storage companies in the United States](https://specstream.ai/data/businesses/b2b-transportation-and-storage-companies/united-states)
- [Forklift dealers in the United States](https://specstream.ai/data/businesses/forklift-dealers/united-states)
